Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma

Ryan, Christopher W., Merimsky, Ofer, Agulnik, Mark, Blay, Jean-Yves, Schuetze, Scott M., Van Tine, Brian A., Jones, Robin L., Elias, Anthony D., Choy, Edwin, Alcindor, Thierry, Keedy, Vicki L., Reed, Damon R., Taub, Robert N., Italiano, Antoine, Garcia del Muro, Xavier, Judson, Ian R., Buck, Jill Y., Lebel, Francois, Lewis, Jonathan J., Maki, Robert G., Schöffski, Patrick·2016·Journal of Clinical Oncology

Abstract

Purpose: Palifosfamide is the active metabolite of ifosfamide and does not require prodrug activation, thereby avoiding the generation of toxic metabolites. The PICASSO III trial compared doxorubicin plus palifosfamide with doxorubicin plus placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma. Patients and Methods: Patients were randomly assigned 1:1 to receive doxorubicin 75 mg/m 2 intravenously day 1 plus palifosfamide 150 mg/m 2/d intravenously days 1 to 3 or doxorubicin plus placebo once every 21 days for up to six cycles. The primary end point was progression-free survival (PFS) by independent radiologic review. Results: In all, 447 patients were randomly assigned to receive doxorubicin plus palifosfamide (n = 226) or doxorubicin plus placebo (n = 221). Median PFS was 6.0 months for doxorubicin plus palifosfamide and 5.2 months for doxorubicin plus placebo (hazard ratio, 0.86; 95% CI, 0.68 to 1.08; P = .19). Median overall survival was 15.9 months for doxorubicin plus palifosfamide and 16.9 months for doxorubicin plus placebo (hazard ratio, 1.05; 95% CI, 0.79 to 1.39; P = .74). There was a higher incidence of grade 3 to 4 adverse events in the doxorubicin plus palifosfamide arm (63.6% v 50.9%) including a higher rate of febrile neutropenia (21.4% v 12.6%). Conclusion: No significant difference in PFS was observed in patients receiving doxorubicin plus palifosfamide compared with those receiving doxorubicin plus placebo. The observed median PFS and overall survival in this large, international study can serve as a benchmark for future studies of doxorubicin in metastatic soft tissue sarcoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.67.6684

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 210

Metadata

Authors
Ryan, C. W., Merimsky, O., Agulnik, M., Blay, J.-Y., Schuetze, S. M., Van Tine, B. A., Jones, R. L., Elias, A. D., Choy, E., Alcindor, T., Keedy, V. L., Reed, D. R., Taub, R. N., Italiano, A., Garcia del Muro, X., Judson, I. R., Buck, J. Y., Lebel, F., Lewis, J. J., Maki, R. G., & Schöffski, P.
Venue
Journal of Clinical Oncology
Published
2016-11-10
Volume
34
Issue
32
Pages
3898-3905
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2520149112
Cited by
210
References
1
FWCI
16.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. https://app.cochat.ai/papers/10.1200/jco.2016.67.6684
The paper
Ryan, C. W., Merimsky, O., Agulnik, M., Blay, J.-Y., Schuetze, S. M., Van Tine, B. A., Jones, R. L., Elias, A. D., Choy, E., Alcindor, T., Keedy, V. L., Reed, D. R., Taub, R. N., Italiano, A., Garcia del Muro, X., Judson, I. R., Buck, J. Y., Lebel, F., Lewis, J. J., . . . Schöffski, P. (2016). PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.6684

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.